Linagliptin as add‐on to empagliflozin and metformin in patients with type 2 diabetes: Two 24‐week randomized, double‐blind, double‐dummy, parallel‐group trials

Aim To evaluate the efficacy and safety of linagliptin vs placebo as add‐on to empagliflozin and metformin in patients with type 2 diabetes. Materials and methods Patients with inadequate glycaemic control despite stable‐dose metformin received open‐label empagliflozin 10 mg (study 1) or 25 mg (study 2) as add‐on therapy for 16 weeks. Subsequently, those with HbA1c ≥7.0 and ≤10.5% (>53 and ≤91 mmol/mol) (N = 482) were randomized to 24 weeks’ double‐blind, double‐dummy treatment with linagliptin 5 mg or placebo in study 1, or to linagliptin 5 mg or placebo in study 2; all patients continued treatment with metformin and empagliflozin 10 mg (study 1) or metformin and empagliflozin 25 mg (study 2). The primary endpoint was change from baseline (defined as the last value before first intake of randomized, double‐blind treatment) in HbA1c at week 24. Results At week 24, HbA1c (mean baseline 7.82‐8.04 [62‐64 mmol/mol]) was significantly reduced with linagliptin vs placebo; adjusted mean ( SE ) differences in change from baseline in HbA1c with linagliptin vs placebo were −.32% (.10) (−3.59 [1.08] mmol/mol) ( P = .001) for patients on empagliflozin 10 mg and metformin, and −0.47% (0.10) (−5.15 [1.04] mmol/mol) ( P < 0.001) for patients on empagliflozin 25 mg and metformin. Adverse events were reported in more patients receiving placebo than in those receiving linagliptin: 55.5% vs 48.4% in study 1 and 58.9% vs 52.7% in study 2. Conclusions Linagliptin as add‐on to empagliflozin and metformin for 24 weeks improved glycaemic control vs placebo, and was well tolerated.